1w72: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 6: | Line 6: | ||
==Overview== | ==Overview== | ||
Antibodies with T cell receptor-like specificity possess a considerable, diagnostic and therapeutic potential, but the structural basis of the, interaction between an antibody and an histocompatibility antigen has so, far not been determined. We present here the crystal structure (at 2.15 A, resolution) of the recombinant, affinity-matured human antibody fragment, Fab-Hyb3 bound to the tumor-associated human leukocyte antigen, (HLA)/peptide complex HLA-A1.MAGE-A1. Fab-Hyb3 employs a diagonal docking, mode resembling that of T cell receptors. However, other than these, natural ligands, the antibody uses only four of its six, complementarity-determining regions for direct interactions with the, target. It recognizes the C-terminal half of the MAGE-A1 peptide, the, HLA-A1 alpha1-helix, and N-terminal residues of the alpha2-helix, accompanied by a large tilting angle between the two types of molecules, within the complex. Interestingly, only a single hydrogen bond between a, peptide side chain and Fab-Hyb3 contributes to the interaction, but large, buried surface areas with pronounced shape complementarity assure high, affinity and specificity for MAGE-A1. The HLA-A1.MAGE-A1.antibody, structure is discussed in comparison with those of natural ligands, recognizing HLA.peptide complexes. | Antibodies with T cell receptor-like specificity possess a considerable, diagnostic and therapeutic potential, but the structural basis of the, interaction between an antibody and an histocompatibility antigen has so, far not been determined. We present here the crystal structure (at 2.15 A, resolution) of the recombinant, affinity-matured human antibody fragment, Fab-Hyb3 bound to the tumor-associated human leukocyte antigen, (HLA)/peptide complex HLA-A1.MAGE-A1. Fab-Hyb3 employs a diagonal docking, mode resembling that of T cell receptors. However, other than these, natural ligands, the antibody uses only four of its six, complementarity-determining regions for direct interactions with the, target. It recognizes the C-terminal half of the MAGE-A1 peptide, the, HLA-A1 alpha1-helix, and N-terminal residues of the alpha2-helix, accompanied by a large tilting angle between the two types of molecules, within the complex. Interestingly, only a single hydrogen bond between a, peptide side chain and Fab-Hyb3 contributes to the interaction, but large, buried surface areas with pronounced shape complementarity assure high, affinity and specificity for MAGE-A1. The HLA-A1.MAGE-A1.antibody, structure is discussed in comparison with those of natural ligands, recognizing HLA.peptide complexes. | ||
==Disease== | |||
Known diseases associated with this structure: Abacavir hypersensitivity, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142800 142800]], Ankylosing spondylitis, susceptibility to, 1 OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142800 142800]], Stevens-Johnson syndrome, susceptibility to OMIM:[[http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=142800 142800]] | |||
==About this Structure== | ==About this Structure== | ||
| Line 34: | Line 37: | ||
[[Category: tcr-like binding]] | [[Category: tcr-like binding]] | ||
''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov | ''Page seeded by [http://ispc.weizmann.ac.il/oca OCA ] on Mon Nov 12 19:47:20 2007'' | ||